Optimize Financial Inc Invests $444,000 in United Therapeutics Corporation $UTHR

Optimize Financial Inc acquired a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the third quarter, HoldingsChannel.com reports. The fund acquired 1,058 shares of the biotechnology company’s stock, valued at approximately $444,000.

Other institutional investors also recently bought and sold shares of the company. WealthCollab LLC lifted its stake in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. increased its stake in United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares during the last quarter. Wilmington Savings Fund Society FSB increased its stake in United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 49 shares during the last quarter. Geneos Wealth Management Inc. raised its holdings in shares of United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 85 shares in the last quarter. Finally, True Wealth Design LLC boosted its position in shares of United Therapeutics by 738.5% during the 3rd quarter. True Wealth Design LLC now owns 109 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 96 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at United Therapeutics

In related news, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $452.07, for a total value of $10,171,575.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 537,914 shares of company stock worth $257,813,558 in the last 90 days. Company insiders own 10.30% of the company’s stock.

United Therapeutics Stock Up 0.9%

UTHR opened at $482.59 on Thursday. The stock’s fifty day moving average is $486.95 and its two-hundred day moving average is $424.86. The company has a market capitalization of $20.78 billion, a P/E ratio of 18.29, a PEG ratio of 2.54 and a beta of 0.85. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $519.99.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on UTHR shares. Wells Fargo & Company boosted their price target on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 30th. HC Wainwright upped their price objective on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Morgan Stanley set a $447.00 price objective on United Therapeutics in a research note on Wednesday, October 29th. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Finally, Royal Bank Of Canada lifted their price target on shares of United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research note on Thursday, October 30th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $509.50.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.